文献速递心脑血管急症消化、代谢与肾脏急症

依洛尤单抗减少无已知显著动脉粥样硬化合并糖尿病患者的首次主要心血管事件:VESALIUS-CV试验结果

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
PubMed 文献 · JAMA · 2026-01-01
一句话结论在无已知显著动脉粥样硬化且合并糖尿病的高危患者中,依洛尤单抗140 mg每2周皮下注射可降低首次主要心血管事件风险。

VESALIUS-CV是一项随机、双盲、安慰剂对照试验,在33个国家774个中心纳入12257例无心肌梗死或卒中史、LDL-C≥90 mg/dL且符合动脉粥样硬化或高危糖尿病标准的患者。本预设亚组分析纳入3655例无已知显著动脉粥样硬化(无既往动脉血运重建、动脉狭窄≥50%或冠状动脉钙化评分≥100 Agatston单位)且均合并糖尿病的患者,随机接受依洛尤单抗140 mg每2周皮下注射或安慰剂。中位随访4.8年,依洛尤单抗组3-P MACE(冠心病死亡、心肌梗死或缺血性卒中)5年Kaplan-Meier估计为5.0%,安慰剂组为7.1%(HR 0.69,95%CI 0.52-0.91,P=0.009)。4-P MACE和全因死亡也显著降低。

要点

  • 无已知显著动脉粥样硬化且合并糖尿病的高危患者,依洛尤单抗组3-P MACE 5年估计5.0% vs 安慰剂组7.1%(HR 0.69,95%CI 0.52-0.91,P=0.009)。
  • 4-P MACE(3-P MACE加缺血驱动的动脉血运重建)依洛尤单抗组5年估计7.6% vs 安慰剂组10.5%(HR 0.69,95%CI 0.55-0.86,P=0.001)。
  • 全因死亡依洛尤单抗组5年估计7.8% vs 安慰剂组10.1%(HR 0.76,95%CI 0.61-0.95)。
  • 48周时中位LDL-C水平依洛尤单抗组52 mg/dL vs 安慰剂组111 mg/dL(P<0.001)。
  • 依洛尤单抗140 mg每2周皮下注射,在 optimally tolerated 他汀治疗基础上加用。

适用人群与场景

  • 无既往心肌梗死或卒中、LDL-C≥90 mg/dL且符合动脉粥样硬化或高危糖尿病标准的患者。
  • 本预设亚组:无已知显著动脉粥样硬化(无既往动脉血运重建、动脉狭窄≥50%或冠状动脉钙化评分≥100 Agatston单位)且均合并糖尿病,共3655例(依洛尤单抗组1849例,安慰剂组1806例),中位年龄65岁,57%女性。

诊断标准与关键阈值

  • 无已知显著动脉粥样硬化定义:无既往动脉血运重建、无动脉狭窄≥50%、无冠状动脉钙化评分≥100 Agatston单位。
  • LDL-C水平≥90 mg/dL为入组条件之一。

处置流程与药物剂量

  • 依洛尤单抗140 mg每2周皮下注射,在 optimally tolerated 他汀治疗基础上加用,安慰剂组使用匹配安慰剂。

研究设计与关键结果

  • VESALIUS-CV为随机、双盲、安慰剂对照试验,在33个国家774个中心纳入12257例患者;本预设亚组分析纳入3655例无已知显著动脉粥样硬化且合并糖尿病患者。
  • 3-P MACE(冠心病死亡、心肌梗死或缺血性卒中):依洛尤单抗组83例(5年Kaplan-Meier估计5.0%)vs 安慰剂组117例(5年Kaplan-Meier估计7.1%),HR 0.69(95%CI 0.52-0.91),P=0.009,组间差异2.1%(95%CI 0.4%-3.8%)。
  • 4-P MACE(3-P MACE加缺血驱动的动脉血运重建):依洛尤单抗组127例(5年Kaplan-Meier估计7.6%)vs 安慰剂组178例(5年Kaplan-Meier估计10.5%),HR 0.69(95%CI 0.55-0.86),P=0.001,组间差异2.9%(95%CI 0.9%-4.9%)。
  • 全因死亡:依洛尤单抗组136例(5年Kaplan-Meier估计7.8%)vs 安慰剂组172例(5年Kaplan-Meier估计10.1%),HR 0.76(95%CI 0.61-0.95)。
  • 48周时中位LDL-C水平:依洛尤单抗组52 mg/dL vs 安慰剂组111 mg/dL(P<0.001)。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照试验的预设亚组分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在无已知显著动脉粥样硬化且合并糖尿病的高危患者中,依洛尤单抗降低首次主要心血管事件风险。

指南或共识出处

  • VESALIUS-CV试验,ClinicalTrials.gov注册号NCT03872401。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis.

OBJECTIVE: To investigate whether evolocumab could prevent a first major cardiovascular event (MACE) in patients without known significant atherosclerosis.

DESIGN, SETTING, AND PARTICIPANTS: VESALIUS-CV was a randomized, double-blind, placebo-controlled trial of evolocumab conducted across 774 sites in 33 countries and enrolling 12 257 patients with no prior myocardial infarction or stroke, LDL-C level 90 mg/dL or greater, and qualifying atherosclerosis or high-risk diabetes. This prespecified subgroup analysis examined outcomes in patients without known significant atherosclerosis (none of the following: prior arterial revascularization, arterial stenosis ≥50%, or coronary artery calcium score ≥100 Agatston units), all of whom had diabetes. Enrollment started in June 2019 and the last patient visit was July 2025, with a median follow-up of 4.8 years.

INTERVENTION: Patients were randomized in a 1:1 ratio to subcutaneous administration of either evolocumab (140 mg every 2 weeks) or matching placebo added to optimally tolerated statin therapy.

MAIN OUTCOMES AND MEASURES: The dual primary end points were composites of coronary heart disease death, myocardial infarction, or ischemic stroke (3-P MACE) and 3-P MACE plus ischemia-driven arterial revascularization (4-P MACE). Secondary end points included all-cause mortality.

RESULTS: This predefined subgroup included 3655 patients (1849 in the evolocumab group and 1806 in the placebo group) with a median age of 65 years (57% female). Among those in the lipid substudy, the median LDL-C level at 48 weeks was 52 mg/dL in the evolocumab group vs 111 mg/dL in the placebo group (P < .001). A 3-P MACE event occurred in 83 patients (5-year Kaplan-Meier estimate, 5.0%) in the evolocumab group compared with 117 patients (5-year Kaplan-Meier estimate, 7.1%) in the placebo group (hazard ratio [HR], 0.69 [95% CI, 0.52-0.91]; P = .009; between-group difference, 2.1% [95% CI, 0.4%-3.8%]). A 4-P MACE event occurred in 127 patients (5-year Kaplan-Meier estimate, 7.6%) in the evolocumab group compared with 178 patients (5-year Kaplan-Meier estimate, 10.5%) in the placebo group (HR, 0.69 [95% CI, 0.55-0.86]; P = .001; between-group difference, 2.9% [95% CI, 0.9%-4.9%]). There were 136 deaths (5-year Kaplan-Meier estimate, 7.8%) in the evolocumab group compared with 172 deaths (5-year Kaplan-Meier estimate, 10.1%) in the placebo group (HR, 0.76 [95% CI, 0.61-0.95]).

CONCLUSIONS AND RELEVANCE: In high-risk patients without known significant atherosclerosis and with diabetes, evolocumab reduced the risk of a first major cardiovascular event.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03872401.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Marston NA, Bohula EA, Bhatia AK, et al. Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. JAMA. 2026. PMID: 41903215. doi:10.1001/jama.2026.3277

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。